From: Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide
References | N | Treatment protocol | Main toxicities |
---|---|---|---|
40 | 30 | STI 400 mg/d + AraC 20 mg/m2/d15–28. | * Hematologic. * Nausea-vomiting. * Fatigue. * Abdominal pain. * Edema. |
41 | 22 | STI 300–800 mg/d + anagrelide 0.5–4 mg/d. | * Hematologic. * Peripheral edema. * Fatigue. * Skin rash. |
42 | 28 | STI 600 mg/d + docetaxel 20–45 mg/m2/d1,8,15,22. | * Hematologic. * Nausea. * Fatigue. |
43 | 20 | STI 400 mg/d + hyper-CVAD. | * Hematologic. * Infections. |
44 | 30 | STI 400 mg/d + hydroxyurea 1 g/d. | * Edema. * Abdominal pain. |
45 | 20 | STI 400/600 mg/d + daunorubicin 50 mg/m2/d1–3 + vincristine 2 mg d1,8,15,22 + prednisolone 60 mg/m2/d1–28 + L-asparaginase 4000 U/m2/d17–28. | * Hematologic. * Hyperbilirubinemia. |
46 | 33 | STI 400/500 mg/d + hydroxyurea 1 g/d. | * Hematologic. |
47 | 9 | STI 300–400 mg/d + doxorubicin 50–60 mg/m2/d1. | * Hematologic. * Nausea-vomiting. * Reduction of LVEF. * Fatigue. |
47 | 7 | STI 300–400 mg/d + gemcitabine 700–800 mg/m2/d1,8,(15). | * Hematologic. * Fatigue. |
48 | 9 | * STI 300–600 mg/d + irinotecan 65 mg/m2 d1,8 + cisplatin 30 mg/m2 d1,8. * STI 300–800 mg/d + irinotecan 60 mg/m2 d1,8,15 + cisplatin 60 mg/m2 d1. | * Hematologic. * Diarrhea. * Thrombosis. * Electrolyte disorder. |
49 | 31 | STI 800 mg/d + vincristine 2 mg d1,8,15,22 + dexamethasone 40 mg d1,2,8,9,15,16,22,23. | * Hematologic. * Infections. * Neuropathy. |
50 | 80 | STI 600 mg/d + cyclophosphamide 1200 mg/m2/d1 + daunorubicin 50 mg/m2/d1–3 + vincristine 1.3 mg/m2/d1,8,15,22 + prednisolone 60 mg/m2/d1–21. | * Hematologic. * Nausea. * Liver dysfunction. |